Peripherally Inserted Central Catheters Market By Product Type (Single-Lumen Catheters, Multi-Lumen Catheters, Antimicrobial Peripherally Inserted Central Catheters), By Application (Cancer Treatment, Nutritional Support, Antibiotic Therapy), By End-User (Hospitals & Clinics, Home Healthcare Providers, Ambulatory Surgical Centers), and By Region; Global Insights & Forecast (2023 – 2030)

As per Intent Market Research, the Peripherally Inserted Central Catheters Market was valued at USD 1.4 billion in 2024-e and will surpass USD 2.4 billion by 2030; growing at a CAGR of 9.3% during 2025 - 2030.

The peripherally inserted central catheters (PICC) market is witnessing substantial growth due to the increasing demand for minimally invasive procedures, particularly for patients requiring long-term intravenous therapy. PICCs are essential for administering medications, fluids, and nutrition to patients, making them an indispensable part of modern healthcare. The market's growth is driven by the rising prevalence of chronic diseases, cancer, and conditions that require extended antibiotic therapy, as well as the growing preference for home healthcare solutions. As an alternative to traditional central venous catheters (CVCs), PICCs offer significant advantages, including lower infection risks, reduced complications, and ease of insertion, which further enhance their adoption in healthcare settings.

PICC lines are widely used across various medical applications, including cancer treatment, nutritional support, and long-term antibiotic therapy. The ability to be inserted into peripheral veins and advance to the central venous system allows for the administration of medications or fluids for an extended period, making it a cost-effective and convenient option for patients requiring long-term care. As healthcare systems continue to evolve with a focus on patient comfort, outpatient care, and reduced hospital stays, the PICC market is expected to see continued growth, with technological advancements improving catheter design and functionality.

Multi-Lumen Catheters Segment is Largest Product Type Owing to Versatility and Multiple Treatment Options

The multi-lumen catheters segment holds the largest share in the peripherally inserted central catheters market, driven by their ability to provide multiple channels for the simultaneous administration of different medications, fluids, or nutrients. Multi-lumen PICCs are essential for patients requiring multiple intravenous treatments, such as those with complex conditions like cancer, sepsis, or multi-drug-resistant infections. These catheters are capable of delivering different therapies without the need for multiple catheter insertions, enhancing both patient comfort and clinical efficiency.

The versatility of multi-lumen catheters makes them particularly useful in critical care environments, where patients often require multiple intravenous lines for various treatments. This segment's dominance is further supported by ongoing advancements in catheter design, such as improved biocompatibility, resistance to infection, and ease of insertion. Multi-lumen catheters are also favored in outpatient settings for long-term therapies, making them integral to the continued growth of the PICC market.

Cancer Treatment Segment is Largest Application Due to Rising Cancer Incidence and Long-Term Therapy Requirements

The cancer treatment segment represents the largest application in the peripherally inserted central catheters market, owing to the increasing incidence of cancer and the need for long-term intravenous access during chemotherapy. PICC lines are essential for cancer patients who require frequent medication administration, including chemotherapy, fluids, and nutritional support. The ability to administer treatments through a single catheter over an extended period reduces the need for repeated needle insertions, enhancing patient comfort and compliance.

As cancer rates rise globally, particularly with an aging population and lifestyle-related risk factors, the demand for PICCs in oncology is expected to remain robust. Additionally, the development of antimicrobial and drug-eluting PICCs has further contributed to their adoption in cancer treatment by reducing the risk of infections and ensuring prolonged catheter functionality during extended treatments. This application segment will continue to lead the market, driven by advancements in cancer care and the increasing need for long-term therapeutic interventions.

Hospitals & Clinics Segment is Largest End-User Due to High Volume of Procedures and Clinical Expertise

The hospitals and clinics segment dominates the end-user category in the peripherally inserted central catheters market, owing to the high volume of PICC procedures conducted in these healthcare settings. Hospitals and clinics are primary centers for the diagnosis, treatment, and management of patients requiring intravenous therapies, making them the largest end-users of PICC lines. These institutions have the necessary infrastructure, skilled medical staff, and patient monitoring systems to perform PICC insertions and manage long-term intravenous therapy effectively.

Hospitals, particularly those with intensive care units and oncology departments, frequently utilize PICCs for managing patients requiring extended antibiotic therapy, nutritional support, or cancer treatments. The clinical expertise available in hospitals ensures that PICC insertions are performed safely, reducing the risk of complications such as infections, thrombosis, or catheter-related bloodstream infections (CRBSIs). As the demand for long-term intravenous access continues to rise, hospitals and clinics will remain the primary drivers of market growth.

Direct Sales Segment is Largest Distribution Channel Owing to Direct Relationship with Healthcare Providers

The direct sales segment leads the peripheral inserted central catheters market in terms of distribution channel, as healthcare providers, including hospitals and clinics, prefer to purchase PICC lines directly from manufacturers or distributors. Direct sales ensure the availability of the latest products and innovations, including antimicrobial PICC lines and advanced multi-lumen catheters. Healthcare providers benefit from having a direct relationship with manufacturers, which enables access to personalized support, training, and product guarantees.

Additionally, direct sales allow manufacturers to offer customized solutions for specific patient needs and healthcare settings, further strengthening the adoption of their products. This distribution channel is preferred in regions with well-established healthcare systems, where hospitals and clinics can work closely with manufacturers to ensure they have access to high-quality PICC lines that meet the latest medical standards.

North America is Largest Region Owing to Advanced Healthcare Infrastructure and High Demand for Long-Term Therapies

North America is the largest region in the peripherally inserted central catheters market, driven by the advanced healthcare infrastructure in the United States and Canada and the high demand for long-term intravenous therapies. The region has a large population of patients with chronic diseases, cancer, and conditions that require prolonged antibiotic therapy, all of which increase the demand for PICC lines. Furthermore, North America's healthcare system is known for its ability to support advanced medical technologies, including the latest developments in PICC lines such as antimicrobial coatings and multi-lumen capabilities.

The preference for outpatient care and home healthcare in North America has also contributed to the region's growth, as PICCs offer a practical solution for patients requiring long-term intravenous access outside of hospital settings. As healthcare trends continue to evolve towards more patient-centric care models, the demand for PICC lines in North America is expected to remain strong, making the region a key market for peripheral inserted central catheters.

Competitive Landscape

The peripherally inserted central catheters market is competitive, with several key players focusing on innovation, product differentiation, and strategic partnerships to expand their market presence. Manufacturers are increasingly developing antimicrobial and multi-lumen PICC lines to meet the growing demand for safer, more effective intravenous therapy solutions. Additionally, companies are investing in research and development to improve the biocompatibility, ease of insertion, and durability of their products.

Strategic collaborations between manufacturers, healthcare providers, and distributors are becoming more common as companies seek to enhance the availability and accessibility of PICCs in global markets. The competitive landscape is expected to remain dynamic, with new product offerings and technological advancements continuing to drive market growth and improve patient care in the peripheral inserted central catheters market.

Recent Developments:

• In December 2024, Becton, Dickinson and Company launched a new antimicrobial PICC catheter designed to reduce infection risks in long-term IV therapies.
• In November 2024, Teleflex Inc. introduced a new multi-lumen PICC catheter aimed at enhancing patient comfort during cancer treatment.
• In October 2024, Medtronic expanded its peripherally inserted central catheter range to include a more flexible model for pediatric patients.
• In September 2024, Cook Medical announced the launch of a new line of single-lumen PICC catheters designed for easier insertion and faster recovery.
• In August 2024, Baxter International Inc. received FDA approval for an innovative long-term catheter placement kit that minimizes complications.

List of Leading Companies:

• Becton, Dickinson and Company
• Teleflex Inc.
• Medtronic
• Cook Medical
• Baxter International Inc.
• C.R. Bard (now part of BD)
• Vygon
• Terumo Corporation
• Johnson & Johnson
• Smiths Medical
• Fresenius Kabi
• Merit Medical Systems
• Nipro Corporation
• AngioDynamics
• Romsons International

Report Scope: